SBC Medical Group Holdings Inc. (NASDAQ: SBC), the Japanese owner and operator of a chain of aesthetic medical clinics, has laid the groundwork for growth in 2026 following a year of significant expansion and strategic initiatives. The company focused on making aesthetic medicine more accessible and differentiating itself through advanced treatments and competitive pricing, resulting in increased clinic numbers, higher repeat business, and enhanced customer loyalty.
As of September 30, 2025, SBC Medical operated 258 franchise locations, a 15% year-over-year increase. The company revised its pricing strategy, leading to a 5% sequential rise in average revenue per customer in the third quarter of 2025. This was fueled by pricing optimization and a multi-brand strategy that attracted higher-revenue-generating customers. Clinics in the franchise network expanded offerings to include specialized medical services such as plastic surgery and infertility treatment, strengthening SBC's market position.
International expansion was a key focus, with entries into Singapore and Thailand, and in early 2026, the company announced its first expansion into the United States. Domestically, SBC launched new brands, including "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo. The latter uses a hybrid dermatology model integrating insurance-covered general dermatology with private-pay aesthetic treatments. Additionally, SBC acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and Waqoo, a related subsidiary, to accelerate research and development and integrate technologies in clinical areas such as AGA and orthopedics.
Financially, SBC Medical reported a significant improvement in net profit in the third quarter of 2025, returning to a more typical cost structure after the absence of IPO-related expenses. Average revenue per visit rose 5% sequentially to $298, and the company ended the quarter with a 72% repeat rate. The company also gained visibility by being added to the Russell 3000 Index, opening it up to a broader base of institutional and individual investors. As noted in the press release, about $10.6 trillion in assets in the U.S. alone are benchmarked against the Russell U.S. indexes. Furthermore, SBC Medical announced a stock buyback program of up to $5 million, underscoring confidence in its growth plan.
With $125 million in cash at the start of the year, SBC Medical made strategic acquisitions and entered new markets. It acquired MB Career Lounge to enhance management support services and added JUN CLINIC, a network of clinics with high average spend per customer, to its network. To capitalize on cosmetic tourism, SBC is targeting Chinese consumers visiting Japan for cosmetic procedures by hiring Chinese-speaking staff, disseminating information on Chinese social media platforms, and holding events in Shanghai. In Singapore, SBC is expanding its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., which operates multiple brands in medical aesthetics. In Thailand, SBC signed an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates over 20 pharmacies and clinics, to provide management support for a new clinic in Bangkok focusing on dermatological treatments.
The aesthetics market in Japan is growing as affluent Chinese and other Asian consumers seek advanced cosmetic treatments, and SBC Medical is positioning itself to meet that demand. With a solid foundation laid in 2025, the company is poised to capitalize on these opportunities in the new year.
